Tranexamic Acid

WASHINGTON, Nov. 17, 2024 /PRNewswire/ -- Having rheumatoid arthritis (RA) was not a risk factor for needing a blood transfusion during or after total knee replacement, according to a new study by HSS researchers presented today at the annual meeting of the American College of Rheumatology, ACR Convergence 2024.¹ Advancements in surgical techniques and the increased use of a medication called tranexamic acid for preventing and controlling bleeding have made it possible for many patients undergoing knee replacement to avoid needing a transfusion, which requires hospital admission for at least a day. Despite these advancements, it was believed that patients with RA undergoing orthopedic surgeries had an elevated risk of transfusion since they tend to have higher rates of anemia compared to the individuals without the disease. RA occurs in about 1% of the general American population.² About 4% of patients having joint replacement surgeries at HSS have the disease. "Learning that rheumatoid arthritis was not a transfusion risk factor was unexpected," said HSS rheumatologist Susan M. Goodman, MD, co-author of the study. "However, we believe presurgical care, including proactively managing chronic anemia before surgery, played a key role in minimizing transfusion risk." For their study, Dr. Goodman, HSS rheumatologist Linda A. Russell, MD, and colleagues analyzed hospital records for more than 29,000 patients who had a single total knee arthroplasty procedure at HSS from February 2016 to December 2022. A total of 822 patients, or 2.8%, received transfusions. The transfusion rate declined significantly during the study period from 5.7% in 2016 to 0.9% in 2022. The investigators reviewed patient demographics such as age and sex, preoperative hemoglobin levels, RA diagnosis and the use of tranexamic acid during surgery, and then looked for associations with transfusion risk. "In addition to finding that rheumatoid arthritis was not a transfusion risk factor, analysis revealed that a higher preoperative hemoglobin level and the use of tranexamic acid significantly decreased transfusion risk, while being male and having a greater burden of other diseases increased risk," said HSS pre-doctoral student and research assistant Stephen Batter, BA, the presenting author of the poster summarizing the study. The research team plans to use their unexpected findings to develop a tool to identify patients with different levels of transfusion risk based on preoperative hemoglobin level, sex, age and health status. This initiative may help orthopedic surgeons better anticipate which patients can safely avoid transfusion and may be suitable candidates for outpatient knee replacement surgery. Authors: Stephen Batter, BA, Huong Do, MA, Dongmei Sun, PhD, Ahmed Deeb, BA, Trang Bui, MD, Jason L. Blevins, MD, Mark P. Figgie, MD, Gwo-Chin Lee, MD, J. Alex B. Gibbons, BA, Bella Mehta, MD, MS, MBBS, Susan M. Goodman, MD, Linda Russell, MD. Reference: ¹ Batter S, Do H, Sun D, Deeb A, Bui T, Blevins J, Figgie M, Lee G, Gibbons J, Mehta B, Goodman S, A Russell L. Investigating Predictors of Transfusion in Rheumatoid Arthritis and Osteoarthritis Patients Undergoing Knee Arthroplasty [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). . Accessed October 10, 2024. ² Xu Y, Wu Q. Prevalence Trend and Disparities in Rheumatoid Arthritis among US Adults, 2005-2018. J Clin Med. 2021;10(15):3289. . Accessed October 10, 2024. About HSS HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 15th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2024-2025), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report "Best Children's Hospitals" list (2024-2025). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a fifth consecutive year (2025). Founded in 1863, the Hospital has the lowest readmission rates in the nation for orthopedics, and among the lowest infection and complication rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. In addition, more than 200 HSS clinical investigators are working to improve patient outcomes through better ways to prevent, diagnose, and treat orthopedic, rheumatic and musculoskeletal diseases. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 165 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. . SOURCE Hospital for Special Surgery WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the third quarter of 2024 and provided a business update. Recent Highlights Commenced enrollment and dosed first subjects in its Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-severe UC;Presented data from two translational studies demonstrating the ex vivo bioactivation of PALI-2108 in stool samples and whole blood at the ACG’s 2024 Annual Scientific Meeting;Reported the completion of refined patient selection strategies based on PDE4-related biomarkers and disease characteristics to optimize clinical outcomes for patients with UC as part of its collaboration with Strand Life Sciences;Completed microbiome study confirming bacterial enzymes for local bioactivation of lead product candidate, PALI-2108, in development for Crohn’s disease and UC;Expanded intellectual property portfolio of PALI-2108 and PALI-1908 with a notice to grant patent from the European Patent Office; andCompleted the first Good Manufacturing Practice (GMP) batch of drug substance PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC. “I am extremely proud of the clinical progress our team has made over this past quarter. The initiation of our Phase 1 clinical trial and patient enrollment and dosing are important milestones in our clinical program,” commented J.D. Finley, Chief Executive Officer of Palisade. “We continue to believe in the potential of PALI-2108 to provide a much-needed solution for UC patients still experiencing significant medical need.” About PALI-2108 PALI-2108 is an orally administered, locally acting colon-specific PDE4 inhibitor prodrug in development for patients affected by UC. The Company continued to progress development of PALI-2108 and recently commenced a Phase 1 single-center, double-blind, placebo-controlled study focused on safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, alongside an open-label study involving a patient cohort with UC. The comprehensive data gathered will support Palisade Bio's precision medicine strategy, aimed at identifying patient responders for future clinical studies. Upcoming Target Milestones Phase 1 topline data expected in the first half of 2025; andInitiate Phase 1b/2a in the second half of 2025. For more information about the Phase 1 clinical study, visit clinicaltrials.gov and reference identifier NCT06663605. Summary of Financial Results for the Quarter Ended September 30, 2024 As of September 30, 2024, the Company had cash and cash equivalents of $8.0 million. The Company believes it has sufficient cash to fund its currently planned operations through the first quarter of 2025. Net loss was $3.5 million for the three months ended September 30, 2024, compared to $3.6 million for the same period in 2023. Research and development expenses of approximately $2.1 million were virtually flat compared to the three months ended September 30, 2023. In the current year period, higher expenses directly related to the joint development of our lead asset, PALI-2108, and higher drug manufacturing costs, were offset by a decrease in costs related to the Company’s development of LB1148, which we ceased in August of 2023, a decrease in other employee-related costs, and the favorable impact of a non-cash gain associated with a decrease in the fair value of our contingent consideration liability. General and administrative expenses decreased by $0.2 million, or 13%, from approximately $1.7 million for the three months ended September 30, 2023 to $1.5 million for the three months ended September 30, 2024. The decrease was primarily due to lower general corporate expenses, which were partially offset by higher consultant and contract labor. About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com. Forward Looking Statements This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; the timing and outcome of our current and anticipated applications and studies related to our product candidates; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company’s ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024, and any Quarterly Reports on Form 10-Q or other SEC filings that were filed thereafter. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLCJenene Thomas 908-824-0775PALI@jtcir.com Palisade Bio, Inc.Condensed Consolidated Balance Sheets (Unaudited)(in thousands, except share and per share amounts) September 30, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $8,040 $12,432 Prepaid expenses and other current assets 830 896 Total current assets 8,870 13,328 Restricted cash 26 26 Property and equipment, net 3 10 Operating lease right-of-use asset 113 198 Other noncurrent assets 324 490 Total assets $9,336 $14,052 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $366 $698 Accrued liabilities 1,509 831 Accrued compensation and benefits 449 778 Current portion of operating lease liability 122 121 Insurance financing debt 235 158 Total current liabilities 2,681 2,586 Warrant liability 2 2 Contingent consideration obligation 45 61 Operating lease liability, net of current portion — 90 Total liabilities 2,728 2,739 Commitments and contingencies Stockholders' equity: Series A Convertible Preferred Stock, $0.01 par value, 7,000,000 shares authorized; 200,000 issued and outstanding at September 30, 2024 and December 31, 2023 2 2 Common stock, $0.01 par value; 280,000,000 shares authorized;1,198,516 and 618,056 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 11 6 Additional paid-in capital 139,195 132,811 Accumulated deficit (132,600) (121,506)Total stockholders' equity 6,608 11,313 Total liabilities and stockholders' equity $9,336 $14,052 Palisade Bio, Inc.Condensed Consolidated Statements of Operations (Unaudited)(in thousands, except share and per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 License revenue $— $— $— $250 Operating expenses: Research and development 2,137 2,104 6,979 5,522 General and administrative 1,456 1,674 4,498 4,644 Total operating expenses 3,593 3,778 11,477 10,166 Loss from operations (3,593) (3,778) (11,477) (9,916)Other (expense) income: Interest expense (6) (8) (9) (11)Other income, net 112 190 392 598 Total other income, net 106 182 383 587 Net loss $(3,487) $(3,596) $(11,094) $(9,329) Net loss available to common stockholders $(3,487) $(3,612) $(11,094) $(9,345)Basic and diluted weighted average shares used in computing basic and diluted net loss per common share 1,500,409 489,624 1,168,277 402,074 Basic and diluted net loss per common share $(2.32) $(7.38) $(9.50) $(23.24) Palisade Bio, Inc.Condensed Consolidated Statements of Cash Flows (Unaudited)(in thousands, except share and per share amounts) Nine Months Ended September 30, 2024 2023 Net loss $(11,094) $(9,329)Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 3 4 Non-cash operating lease expense 85 76 Recurring fair value measurements of liabilities (159) 153 Issuance of common stock to vendors 124 — Loss on disposal of property and equipment 4 — Stock-based compensation and related charges 575 439 Other — (108)Changes in operating assets and liabilities: Prepaid and other current assets and other noncurrent assets 542 596 Accounts payable and accrued liabilities 526 (184)Accrued compensation and benefits (329) 43 Operating lease liabilities (89) (77)Net cash used in operating activities (9,812) (8,387)Cash flows from investing activities: Purchases of property and equipment — (4)Net cash used in investing activities — (4)Cash flows from financing activities: Payments on insurance financing debt (270) (290)Proceeds from issuance of common stock and warrants 4,000 9,419 Proceeds from the exercise of warrants 2,503 2,758 Payment of warrant inducement issuance costs (343) — Payment of equity issuance costs (456) (567)Proceeds from issuance of common stock under Employee Stock Purchase Plan 11 — Shares withheld for payment of employee withholding tax liability (25) — Net cash provided by financing activities 5,420 11,320 Net (decrease) increase in cash, cash equivalents and restricted cash (4,392) 2,929 Cash, cash equivalents and restricted cash, beginning of year 12,458 12,409 Cash, cash equivalents and restricted cash, end of period $8,066 $15,338 Reconciliation of cash, cash equivalents and restricted cash to the balance sheets: Cash and cash equivalents $8,040 $15,312 Restricted cash 26 26 Total cash, cash equivalents and restricted cash $8,066 $15,338